News

In a recent study, a team of scientists at the Stowers Institute for Medical Research discovered that a specific genetic locus in the DNA, Dlk1-Gtl2, plays a key role in protecting adult blood-forming stem cells, called adult hematopoietic stem cells, by inhibiting mitochondria’s metabolic activity. The study, entitled “…

A team of researchers recently investigated the therapeutic potential of salvianolic acid B in non-alcoholic steatohepatitis (NASH) disease. Their study, “Effects of salvianolic acid B on liver mitochondria of rats with nonalcoholic steatohepatitis,” was published in the World Journal of Gastroenterology. NASH is a type of nonalcoholic fatty liver diseases (NAFLD),…

A new study published in the journal Cell Metabolism revealed that exercise can energize brain cell function in animal models by increasing the levels of a specific mitochondrial enzyme. The finding may have important therapeutic implications for the treatment of age-related cognitive decline and neurodegenerative diseases. The study…

In recent study, a team of researchers from the University of Pennsylvania and Rockefeller University hypothesize that abnormal mitochondrial functions could affect — by differentially modulating — an organism’s multisystemic response to psychological stress.  The article, published in the journal Proceedings of the National Academy of Sciences of the United…

In a new study entitled “A Metabolic Signature of Mitochondrial Dysfunction Revealed through a Monogenic Form of Leigh Syndrome,” a team of scientists performed a metabolomics analysis of plasma and urine samples from patients with Leigh syndrome and found a distinct metabolic signature of mitochondrial dysfunction. The study was…

Viking Therapeutics, Inc., a biopharmaceutical company specializing in therapies for endocrine and metabolic conditions, recently announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its drug candidate VK2809. Viking is planning a Phase 2 clinical trial of VK2809 for the…

A study recently published in the journal Stem Cell Reports revealed a new method to significantly reduce the time necessary to reprogram and genetically correct stem cells to be used in therapeutic regenerative medicine, including for mitochondrial diseases. The study is entitled “Simultaneous Reprogramming…

DeuteRx LLC, a Boston-based biotechnology company dedicated to the improvement of marketed and candidate drugs, recently announced it will give an oral presentation on its candidate product DRX-065 at the ongoing American Association for the Study of Liver Diseases (AASLD) Annual Meeting. The presentation, entitled “DRX-065, the stabilized R-enantiomer…

A mitochondrial defect causes maternally inherited, nonsyndromic deafness, an extreme case of tissue-specific mitochondrial pathology. Now, in a study published in the American Journal of Pathology, a team of researchers using a transgenic mouse model with a mitochondrial defect that causes an analogous premature hearing loss discovered…

NeuroVive Pharmaceutical AB, a company focused on the development of therapeutic drug candidates to treat mitochondrial diseases, announced in a press release the presentation of the first preclinical results from its Complex I Deficiency discovery program at the 6th World Congress on Targeting Mitochondria in Berlin, Germany. Complex I…